JP2023502053A - デング病の治療及び予防 - Google Patents

デング病の治療及び予防 Download PDF

Info

Publication number
JP2023502053A
JP2023502053A JP2022528008A JP2022528008A JP2023502053A JP 2023502053 A JP2023502053 A JP 2023502053A JP 2022528008 A JP2022528008 A JP 2022528008A JP 2022528008 A JP2022528008 A JP 2022528008A JP 2023502053 A JP2023502053 A JP 2023502053A
Authority
JP
Japan
Prior art keywords
compound
log
copies
dose
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022528008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502053A5 (cg-RX-API-DMAC7.html
Inventor
ゲタルス,オリヴィア,ガブリエラ,エム
ケステルイン,バート,ルドルフ,ロマニー
ストープス,バート,ヘンリ,テレジア
ボンファンティ,ジャン-フランソワ
ヨンカース,ティム,ヒューゴ,マリア
ローク,マルニクス ファン
カプテイン,スザンヌ
ネイツ,ヨハン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KU Leuven
Original Assignee
KU Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KU Leuven filed Critical KU Leuven
Publication of JP2023502053A publication Critical patent/JP2023502053A/ja
Publication of JP2023502053A5 publication Critical patent/JP2023502053A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022528008A 2019-11-15 2020-11-13 デング病の治療及び予防 Pending JP2023502053A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19209593.3 2019-11-15
EP19209593 2019-11-15
EP19213851.9 2019-12-05
EP19213851 2019-12-05
EP20171172 2020-04-23
EP20171172.8 2020-04-23
PCT/EP2020/082102 WO2021094563A1 (en) 2019-11-15 2020-11-13 Treatment and prevention of dengue disease

Publications (2)

Publication Number Publication Date
JP2023502053A true JP2023502053A (ja) 2023-01-20
JP2023502053A5 JP2023502053A5 (cg-RX-API-DMAC7.html) 2023-11-21

Family

ID=73288639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528008A Pending JP2023502053A (ja) 2019-11-15 2020-11-13 デング病の治療及び予防

Country Status (14)

Country Link
US (1) US12702657B2 (cg-RX-API-DMAC7.html)
EP (1) EP4058019A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023502053A (cg-RX-API-DMAC7.html)
KR (1) KR20220101679A (cg-RX-API-DMAC7.html)
CN (1) CN114980884A (cg-RX-API-DMAC7.html)
AU (1) AU2020382911A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009199A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161338A1 (cg-RX-API-DMAC7.html)
IL (1) IL292970A (cg-RX-API-DMAC7.html)
MX (1) MX2022005879A (cg-RX-API-DMAC7.html)
PH (1) PH12022551160A1 (cg-RX-API-DMAC7.html)
TW (1) TW202132269A (cg-RX-API-DMAC7.html)
UA (1) UA129409C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021094563A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119173261A (zh) * 2022-05-12 2024-12-20 杨森制药公司 登革热病毒感染的治疗和/或预防
WO2025248536A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel oxime derivatives to treat viral infections
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515495A (ja) * 2015-05-08 2018-06-14 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての一または二置換インドール誘導体

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1200899A (en) 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
EP1261610A2 (en) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
EP1749007A2 (en) 2004-03-30 2007-02-07 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
NZ555142A (en) 2004-12-23 2010-03-26 Novartis Ag Compounds for flaviviridae treatment
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
AU2006221080A1 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
DE102005028845A1 (de) 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
CN101253152A (zh) 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
CN102056483A (zh) 2008-06-03 2011-05-11 西佳技术公司 用于治疗或预防登革病毒感染的小分子抑制剂
MX2011001872A (es) 2008-08-18 2011-05-23 Univ Yale Moduladores de mif.
EP2331499B1 (en) 2008-08-19 2016-09-21 Janssen Pharmaceutica NV Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
CA2771124C (en) 2009-09-09 2019-01-15 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EA201290575A1 (ru) 2010-01-15 2013-01-30 Джилид Сайэнс, Инк. Ингибиторы вирусов flaviviridae
WO2011120025A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JP6505727B2 (ja) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環
KR102382905B1 (ko) 2014-06-04 2022-04-04 프레드 헛친슨 켄서 리서치 센터 노치 1 및/또는 노치 2 작용제를 사용한 줄기 세포의 확장 및 생착
KR102391259B1 (ko) 2014-06-04 2022-04-26 암젠 인크 포유류 세포 배양물을 회수하는 방법
BR112017006708A2 (pt) 2014-10-01 2017-12-26 Janssen Pharmaceuticals Inc indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
US9944598B2 (en) 2014-10-01 2018-04-17 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
NO2721243T3 (cg-RX-API-DMAC7.html) 2014-10-01 2018-10-20
ES2896198T3 (es) 2014-10-10 2022-02-24 Univ Rutgers Cebadores y sondas de reacción en cadena de polimerasa para Mycobacterium tuberculosis
PH12017501272B1 (en) 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JP6636133B2 (ja) 2015-07-22 2020-01-29 オメイコス セラピューティクス ゲーエムベーハー 心疾患の治療に対するcyp−エイコサノイドの代謝的にロバストな類縁体
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3002214C (en) 2015-11-03 2022-01-04 Zoetis Services Llc Sol-gel polymer composites and uses thereof
EP3433274A1 (en) 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
UY37174A (es) 2016-03-31 2017-10-31 Takeda Pharmaceuticals Co Un compuesto heterocíclico que tiene una acción inhibidora de monoacilglicerol lipasa
AU2017240801A1 (en) 2016-04-01 2018-10-25 Amgen Inc. Chimeric receptors to FLT3 and methods of use thereof
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
SG10201912519VA (en) 2016-04-01 2020-02-27 Kite Pharma Inc Chimeric receptors and methods of use thereof
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018012016A (es) 2016-04-01 2019-01-24 Basf Se Compuestos biciclicos.
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515495A (ja) * 2015-05-08 2018-06-14 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての一または二置換インドール誘導体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ROTEM BEN-SHACHAR ET AL.: "Drivers of Inter-individual Variation in Dengue Viral Load Dynamics", PLOS COMPUTATIONAL BIOLOGY, vol. 12 (11), JPN7024004697, 2016, pages 1005194, ISSN: 0005452636 *
WEI-KUNG WANG ET AL.: "High Levels of Plasma Dengue Viral Load during Defervescence in Patients with Dengue Hemorrhagic Fev", VIROLOGY, vol. 305, JPN7024004698, 2003, pages 330 - 338, ISSN: 0005452635 *
忽那 賢志: "デング熱(Dengue fever)", 感染症クイックリファレンス, JPN7024004700, 2019, ISSN: 0005677431 *
高崎 智彦: "デング熱とは", 国立感染戦研究所 感染症情報, JPN7024004699, 2014, ISSN: 0005677432 *

Also Published As

Publication number Publication date
EP4058019A1 (en) 2022-09-21
UA129409C2 (uk) 2025-04-16
US12702657B2 (en) 2026-08-11
MX2022005879A (es) 2022-06-14
TW202132269A (zh) 2021-09-01
KR20220101679A (ko) 2022-07-19
IL292970A (en) 2022-07-01
AU2020382911A1 (en) 2022-06-30
CN114980884A (zh) 2022-08-30
CA3161338A1 (en) 2021-05-20
WO2021094563A1 (en) 2021-05-20
PH12022551160A1 (en) 2023-09-25
BR112022009199A2 (pt) 2022-07-26
US20220409583A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
US20240269125A1 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
JP2023502530A (ja) Hiv予防のためのカプシド阻害剤
KR20220101679A (ko) 뎅기열 질환의 치료 및 예방
JP2021515769A (ja) カプシド集合調節剤の投薬レジメン
AU2014228035B2 (en) Novel dosing regimens of celgosivir for the treatment of dengue
CA2945825C (en) Inhibition of flaviviruses or chikungunya viruses using retinoic acid analogues
RU2738885C1 (ru) Противо-SARS-CoV-2 вирусное средство Антипровир
KR102568877B1 (ko) 중증열성혈소판감소증후군 치료 또는 예방용 약학 조성물 및 이의 의약 용도
JP2023502053A5 (cg-RX-API-DMAC7.html)
EP4349335A1 (en) Use of 5-nitro-8-hydroxyquinoline
CN102335171B (zh) 一类n-(2-噻唑)苯甲酰胺衍生物的应用
HK40074715A (en) Treatment and prevention of dengue disease
EA049504B1 (ru) Лечение и профилактика лихорадки денге
EA022711B1 (ru) Комбинация дибромида 1,12-додекаметилен-бис-[4-метил-5-(2-гидроксиэтил)тиазолия] и артесуната для лечения тяжелой формы малярии
KR102475176B1 (ko) 정맥내 항바이러스 치료
KR20210129579A (ko) 사스 코로나바이러스 감염증 치료용 약학적 조성물
CN114728006A (zh) 治疗冠状病毒感染的方法
HUT76546A (en) Combinative pharmaceutical compositions and therapy for treating hiv infection
JP2009533428A (ja) 筋肉内抗ウイルス処置
RU2407738C1 (ru) Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
GB2292081A (en) The use of a Neuraminidase Inhibitor in combination with an Influenza Vaccine
JPWO2003047591A1 (ja) 肺高血圧症予防治療剤
Li et al. A dual‐acting dengue inhibitor targeting NS5 RdRp-3′ UTR interaction while restoring endoplasmic reticulum homeostasis
KR20210129613A (ko) 사스 코로나바이러스 감염증 치료용 약학 조성물 및 이의 의약 용도
JP2024533532A (ja) コロナウイルス感染症を処置するための新規の併用薬物、医薬組成物およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902